New antibiotic tackles tough infections in vulnerable cancer patients
NCT ID NCT04673175
First seen Jan 28, 2026 · Last updated May 20, 2026 · Updated 18 times
Summary
This study tested the antibiotic ceftolozane-tazobactam in 17 people with blood cancers or who had a stem cell transplant and developed a serious Pseudomonas infection. The goal was to see if the drug could help patients survive and clear the infection within 30 days. Participants received the antibiotic through a vein for 10 to 14 days. The study was stopped early, but the results help doctors understand how to treat these dangerous infections in high-risk patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.